| Literature DB >> 35867919 |
Nayanna De Oliveira Ramos Melo1, Hélio De Sousa Peres Júnior2, Clara Araujo Diniz3, Matheus De Sousa Silva4, Telma Leda Gomes de Lemos5, Francisco Vagnaldo Fechine Jamacaru6, Conceição Aparecida Dornelas7.
Abstract
Introduction. Cyclophosphamide (CP) is used to treat malignant neoplasias and control autoimmune diseases. Still, one of its metabolites, acrolein, is toxic to the urothelium and can lead to hemorrhagic cystitis and severe discomfort. Objective. To evaluate the ability of red propolis to prevent and treat CP-induced hemorrhagic cystitis in rats. Materials and methods. Red propolis was extracted in 1% gum arabic and administered subcutaneously (sc). In the first experiment, groups IA, IIA, and IIIA and groups IB, IIB, and IIIB received water, gum arabic (GA), or propolis, respectively, for 30 days. Then water (controls) or CP (treatment) was administered i.p. In the second experiment, groups IVA, VA, and VIA received water i.p. while groups IVB, VB, and VIB received CP i.p. This was followed by 5 injections at 2-hour intervals with either water, GA, or propolis. Bladder tissue was examined according to Gray’s criteria. Results. The total inflammatory histology score was significantly smaller in group VIB (11.33 ± 2.07). Mild inflammation predominated in group VIB while most of the animals in group IVB had severe inflammation (p=0.0375). Ulcers were predominantly multiple in Groups IVA and VB but rare or absent in Group VIB (p=0.0118). Urothelial cells were mostly absent in groups IVB and VB and present/normal in group VIB (p=0.0052). Fibrin was abundant in groups IVB and VA but mostly absent in group VIB (p=0.0273). Conclusions. Red propolis can reduce inflammation in CP-induced hemorrhagic cystitis in rats.Entities:
Keywords: Cystitis; cyclophosphamide; propolis; models; animal
Mesh:
Substances:
Year: 2022 PMID: 35867919 PMCID: PMC9365036 DOI: 10.7705/biomedica.6087
Source DB: PubMed Journal: Biomedica ISSN: 0120-4157 Impact factor: 1.173
Figure 1Design of the experiments
Figure 2. A .Swollen bladder with telangiectasia from group IB (treatment). B. Bladder from Group IA (control)
Figure 3.Mean bladder weight (g) in groups IA, IB, IIA, IIB, IIIA, and IIIB
Figure 4.Mean bladder weight (g) in groups IVA, IVB, VA, VB, VIA, and VIB
Figure 5.Total histological scores (mean ± standard deviation) in groups IVB, VB, and VIB according to Gray’s criteria
Presence of urothelial cells in bladders from groups IVB, VB, and VIB
| Group | Urothelial cells | Total | |
|---|---|---|---|
| Present (normal) | Absent | ||
| IVB | 0 (0.00%) | 6 (100%) | 6 (100.00%) |
| VB | 1 (16.67%) | 5 (83.33%) | 6 (100.00%) |
| VIB | 5 (83.33%) | 1 (16.67%) | 6 (100.00%) |
| Total | 6 | 12 | 18 |
Chi-squared test
Level of inflammation in groups IVB, VB and VIB
| Group | Inflammation | Total | ||
|---|---|---|---|---|
| Mild | Moderate | Severe | ||
| IVB | 0 (0.00%) | 1 (16.67%) | 5 (83.33%) | 6 (100.00%) |
| VB | 2 (33.33%) | 1 (16.67%) | 3 (50.00%) | 6 (100.00%) |
| VIB | 5 (83.33%) | 1 (16.67%) | 0 (0.00%) | 6 (100.00%) |
| Total | 7 | 3 | 8 | 18 |
Chi-squared test
Presence of ulcers in Groups IVB, VB, and VIB
| Group | Ulcers | Total | |
|---|---|---|---|
| Absent/rare | Multiple | ||
| IVB | 0 (0.00%) | 6 (100.00%) | 6 (100.00%) |
| VB | 2 (33.33%) | 4 (66.67%) | 6 (100.00%) |
| VIB | 5 (83.33%) | 1 (16.67%) | 6 (100.00%) |
| Total | 7 | 11 | 18 |
Chi-squared test
Presence of fibrin in groups IVB, VB, and VIB
| Group | Fibrin | Total | |
|---|---|---|---|
| Absent | Present | ||
| IVB | 0 (0.00%) | 6 (100.00%) | 6 (100.00%) |
| VB | 1 (16.67%) | 5 (83.33%) | 6 (100.00%) |
| VIB | 4 (66.67%) | 2 (33.33%) | 6 (100.00%) |
| Total | 5 | 13 | 18 |
Chi-squared test
Histological change in groups IVB, VB, and VIB
| Group | Histological change | Total | |
|---|---|---|---|
| Normal/mild | Severe | ||
| IVB | 1 | 5 | 6 |
| VB | 2 | 4 | 6 |
| VIB | 5 | 1 | 6 |
| Total | 8 | 10 | 18 |
Chi-squared test
Figure 6.Slices of bladder wall stained with H&E (magnification: 100X). A. Group IVA; normal aspect. B. Group IVB; edema and inflammatory infiltrate in the submucosa and large amount of fibrin and red blood cells in the bladder lumen (black arrow). C. Group VA; normal aspect. D. Group VB; inflammatory infiltrate in the submucosa and large amount of fibrin and red blood cells in the bladder lumen. E. Group VIA; normal aspect. F. Group VIB; inflammatory infiltrate in the submucosa and fibrin and red blood cells in the bladder lumen significantly reduced in relation to Group IVB (B), despite accentuated edema in the submucosa (white arrow).